Clinical Trial Phases Explained

What Phase 1 through Phase 4 mean for patients, how long each takes, and what to expect at every stage.

By Victor Lafforgue, Founder of TrialsAlert. See our editorial policy for how we source and review content.

What are clinical trial phases?

Clinical trial phases are the stages of testing that every new treatment must pass through before it can be approved for widespread use. Each phase has a specific purpose, tests the treatment in a different number of people, and answers different scientific questions. Understanding these phases helps patients evaluate how far along a treatment is in its development and what the results mean for their condition. The entire process from Phase 1 to approval typically takes 10 to 15 years, though breakthrough treatments for serious conditions can receive accelerated timelines through expedited regulatory pathways. Not every treatment that enters Phase 1 will make it to approval. Approximately 14% of all drugs that enter clinical trials ultimately receive FDA approval.

Phase 1: Safety and dosage (20-100 participants)

Phase 1 trials are the first time a treatment is tested in humans. The primary goal is to determine whether the treatment is safe and to find the right dosage. Researchers start with very low doses and gradually increase them, monitoring participants closely for side effects. These trials typically involve 20 to 100 healthy volunteers or patients with the target condition. About 70% of treatments pass Phase 1. Phase 1 trials usually last several months and take place at a single research center.

Phase 2: Effectiveness (100-300 participants)

Phase 2 trials test whether the treatment actually works for the intended condition. Researchers monitor both effectiveness and side effects in 100 to 300 patients who have the condition the treatment targets. This phase lasts from several months to two years. Only about 33% of treatments pass Phase 2, making it the most significant hurdle in drug development. Many promising treatments fail here because they do not show enough benefit compared to existing options.

Phase 3: Large-scale comparison (1,000-3,000+ participants)

Phase 3 trials are the gold standard for determining whether a treatment should be approved. They test the treatment in 1,000 to 3,000 or more patients across multiple research sites, often in multiple countries. The treatment is compared against the current standard of care or a placebo using randomized, double-blind methods. About 58% of treatments that reach Phase 3 ultimately receive approval. These trials generate the evidence that regulatory agencies like the FDA and EMA review when deciding whether to approve a new treatment.

Phase 4: Post-approval monitoring

Phase 4 trials occur after a treatment has been approved and is available to the public. They monitor long-term safety, identify rare side effects that may not have appeared in smaller trials, and study optimal dosing in broader patient populations. These studies are critical for understanding how a treatment performs in the real world beyond the controlled environment of earlier phases.

Want this done for you?

TrialsAlert scans ClinicalTrials.gov daily, matches trials to your condition using AI, and sends you a plain-language weekly briefing. No searching, no jargon, no missed trials. Start monitoring your condition.